Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ReCode Therapeutics

< Previous 1 2 Next >
News headline image
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Announces Two Key Additions to Scientific Advisory Board
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Participate in Upcoming Investor Conferences
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
From ReCode Therapeutics
Via Business Wire
News headline image
New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Participate in May Conferences
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Participate in February Conferences
From ReCode Therapeutics
Via Business Wire
News headline image
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
Tickers NTLA
News headline image
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Participate in November Conferences
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces Closing of Extension to Series B Financing
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Present at September Investor Conferences
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Present at Jefferies Healthcare Conference
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia
From ReCode Therapeutics
Via Business Wire
News headline image
Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From ReCode Therapeutics
Via Business Wire
News headline image
ReCode Therapeutics Appoints Trisha Millican to Board of Directors
From ReCode Therapeutics
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.